قالب:Available forms of progesterone

Available forms of progesterone[sources 1][أ]
Route Form Dose Brand name Availability[ب]
Oral Capsule 100, 200, 300 mg Prometrium[ت] Widespread
Tablet (SR) 200, 300, 400 mg Dubagest SR[ت] India
Sublingual Tablet 10, 25, 50, 100 mg Luteina[ت] Europe[ث]
Transdermal Gel[ج] 1% (25 mg) Progestogel Europe
Vaginal Capsule 100, 200, 300 mg Utrogestan Widespread
Tablet 100 mg Endometrin[ت] Widespread
Gel 4, 8% (45, 90 mg) Crinone[ت] Widespread
Suppository 200, 400 mg Cyclogest Europe
Ring 10 mg/day[ح] Fertiring[ت] South America[خ]
Rectal Suppository 200, 400 mg Cyclogest Europe
Uterine IUD 38 mg Progestasert Discontinued
Intramuscular
injection 		Oil solution 2, 5, 10, 20, 25,
50, 100 mg/mL		 Proluton[ت] Widespread
Aq. susp. 12.5, 30, 100 mg/mL Agolutin[ت] Europe[د]
Emulsion 5, 10, 25 mg/mL Di-Pro-Emulsion Discontinued
Microsph. 20, 100 mg/mL ProSphere[ت] Mexico
Subcutaneous Aq. soln. (inj.) 25 mg/vial Prolutex Europe
Implant 50, 100 mg Proluton[ت] Discontinued
Intravenous Aq. soln. (inj.) 20 mg/mL Primolut Discontinued
Sources and footnotes:
  1. ^ Sources: [1][2][3][4][5][6][7][8][9][10][11]
  1. ^ This table only includes products where progesterone is the sole active ingredient.
  2. ^ See also: Progesterone (medication) § Availability
  3. ^ أ ب ت ث ج ح خ د ذ ر Other brand names exist.
  4. ^ Specifically in Poland and Ukraine.
  5. ^ For local application to the breasts; negligible systemic effect.
  6. ^ One progesterone vaginal ring provides 10mg of progesterone each day for 3 months.
  7. ^ Specifically in Chile, Ecuador, and Peru.
  8. ^ Specifically the Czech Republic and Slovakia.
Template documentation

See also

References

  1. ^ "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration. Retrieved 26 July 2018.
  2. ^ Engel J, Kleemann A, Kutscher B, Reichert D (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 1145–. ISBN 978-3-13-179275-4.
  3. ^ Becker KL (2001). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins. pp. 2168–. ISBN 978-0-7817-1750-2.
  4. ^ Anita MV, Jain S, Goel N (31 July 2018). Use of Progestogens in Clinical Practice of Obstetrics and Gynecology. JP Medical Ltd. pp. 4–. ISBN 978-93-5270-218-3.
  5. ^ Sauer MV (1 March 2013). Principles of Oocyte and Embryo Donation. Springer Science & Business Media. pp. 7, 117–118. ISBN 978-1-4471-2392-7.
  6. ^ Elder K, Dale B (2 December 2010). In-Vitro Fertilization. Cambridge University Press. pp. 26–. ISBN 978-1-139-49285-0.
  7. ^ "PROSPHERE CARNOT". Archived from the original on 2019-12-30.
  8. ^ Heinrich Kahr (8 March 2013). Konservative Therapie der Frauenkrankheiten: Anzeigen, Grenzen und Methoden Einschliesslich der Rezeptur. Springer-Verlag. pp. 21–. ISBN 978-3-7091-5694-0.
  9. ^ Basic Sex Hormone Therapy. Schering A.G. 1962. p. 96.
  10. ^ Current Medicine and Drugs. 1962. p. 40. Primolut Intravenous (Schering A.G. Berlin)
  11. ^ Haleem S, Khan MI (March 2015). "Changing Indian Market Trends of NMP: A Review" (PDF). International Journal of Pharma Research & Review. 4 (3): 28–30. ISSN 2278-6074. S2CID 74224514.
تمّ الاسترجاع من "https://www.marefa.org/w/index.php?title=قالب:Available_forms_of_progesterone&oldid=4311195"